样式: 排序: IF: - GO 导出 标记为已读
-
Barriers to digital endpoints in data collection in low and middle-income countries Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-03-13 Ahmad Z. Al Meslamani
Published in Expert Review of Pharmacoeconomics & Outcomes Research (Just accepted, 2024)
-
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-03-12 Hong Juan, Chen Tujia, Ouyang Lihui, Du Ning, Li Anna, Zhou Zhongqi, Zhang HaiLing, Xia Zhengzheng, Meng Jun
CDK4/6 inhibitors dalpiciclib and abemaciclib have been approved by the Chinese National Medical Products Administration as first-line treatment for postmenopausal females with hormone receptor-pos...
-
Development of data processing algorithm to calculate adherence for adults with cystic fibrosis using inhaled therapy – a multi-center observational study within the CFHealthHub learning health system Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-03-08 Robert D Sandler, Lana Lai, Sophie Dawson, Sarah Cameron, Aoife Lynam, Matthew Sperrin, Zhe Hui Hoo, Martin J Wildman
We aimed to develop a robust algorithm for accurately calculating ‘daily complete dose counts’ for inhaled medicine using electronically captured nebulizer data within the CFHealthHub Learning Heal...
-
Health-related quality of life measured using the EQ-5D-3L: Iranian Population Norms Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-03-07 Abdoreza Mousavi, Ali Akbari Sari, Fakhroddin Dastari, Rajabali Daroudi
Normative values are valuable for comparing a specific population with the general population, making them particularly useful in disease burden studies and cost-effectiveness analysis. The objecti...
-
The clinical and economic burden of illness in the first two years after ostomy creation: a nationwide Danish cohort study Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-03-04 Frederikke Bruun Andersen, Jakob Kjellberg, Rikke Ibsen, Catarina Sternhufvud, Birte Petersen
Living with an ostomy is often associated with costly complications. This study examined the burden of illness the first two years after ostomy creation.Data from Danish national registries include...
-
Consolidated Health economic evaluation reporting standards 2022 (CHEERS II) statement: a validated Dutch translation Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-02-24 Amber Werbrouck, Esther de Bekker-Grob, Maiwenn Al, Koen Putman, Ruben Willems
This study primarily aimed to develop a validated Dutch translation of the 28 items of the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) II. A secondary aim was to provide a ...
-
Using real world evidence to optimize care: the case of medical cannabis Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-02-23 Anne Katrin Schlag, David J Nutt, Michael Lynskey
Published in Expert Review of Pharmacoeconomics & Outcomes Research (Ahead of Print, 2024)
-
Using natural language processing to analyze unstructured patient-reported outcomes data derived from Electronic Health Records for cancer populations: a systematic review Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-02-21 Jin-Ah Sim, Xiaolei Huang, Madeline R. Horan, Justin N. Baker, I-Chan Huang
Patient-reported outcomes (PROs; symptoms, functional status, quality-of-life) expressed in the ‘free-text’ or ‘unstructured’ format within clinical notes from electronic health records (EHRs) offe...
-
Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-02-19 Shih Ping Lai, Shyh-Yau Wang, Agnes LF Chan, John Hang Leung, Hei-Tung Yip
The cost-effectiveness of adding bevacizumab biosimilar with or without chemotherapy (CT) and drug wastage in treating platinum-resistant recurrent ovarian cancer (PRrOC) was assessed.A three-state...
-
A proposal of actions for stakeholders and policy makers to address the global burden of headache disorders by 2030: why is this important for global health? Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-02-19 Alberto Raggi, Matilde Leonardi, Paolo Martelletti
Published in Expert Review of Pharmacoeconomics & Outcomes Research (Just accepted, 2024)
-
The long-term clinical impact of digital endpoints and biomarkers in data collection Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-02-19 Ahmad Z. Al Meslamani
Published in Expert Review of Pharmacoeconomics & Outcomes Research (Ahead of Print, 2024)
-
The impact of non-pharmacological interventions on adherence to medication and persistence in Dyslipidaemia and hypertension: a systematic review Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-02-17 André Pascal Kengne, Jean-Baptiste Brière, Irene Asensio Gudiña, Xiaobin Jiang, Petya Kodjamanova, Liga Bennetts, Zeba M Khan
Suboptimal medication adherence is common among patients with cardiovascular diseases. We sought evidence on non-pharmacological interventions used to support adherence for patients with hypertensi...
-
Policy Solutions for Medication Non-Adherence: what can governments do? Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-02-17 Ahmad Z. Al Meslamani
Published in Expert Review of Pharmacoeconomics & Outcomes Research (Just accepted, 2024)
-
Economic evaluation of clinical pharmacy service using integrated health system in tertiary care hospital Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-02-16 Muhammad Amir, Ale Zehra, Rabya Munawar, Wajiha Gul, Tehreem Fatima, Younas Khan, Razia Jaffery, Zaheer-Ud-Din Babar
Clinical pharmacy services are the specialized practices of pharmacists to provide pharmaceutical care. All these activities are documented as pharmacist interventions to avoid medication errors wh...
-
Meta-analysis of traditional Chinese medicine on chronic kidney disease Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-02-09 Xian-Ya Wang, Shu-Hua Zhao, An-Na Wang, Di Zou
To explore the effect of traditional Chinese medicine (TCM) on the treatment of chronic kidney disease (CKD).Databases were used for literature research until 16 December 2022, including PubMed, Co...
-
Impact of AML on patient and caregiver workplace absenceWork absenteeism, disability, and lost wages among patients with acute myeloid leukemia and caregivers: a cohort study using US administrative claims and productivity data Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-31 Bhavik J. Pandya, Christopher Young, Elizabeth R. Packnett, Bin Xie, Timothy Lillehaugen, Alana Block, Katarzyna Bernacki, Maelys Touya, Thomas W. LeBlanc
To describe the impact of acute myeloid leukemia (AML) diagnosis on workplace absenteeism and disability days among patients and their caregivers.This retrospective study included adults with newly...
-
leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-29 Jorge Mestre-Ferrandiz, Marcin Czech, Josef S. Smolen, Paul Cornes, Matti S. Aapro, Silvio Danese, Stephen Deitch, Hannah Tyldsley, Will Foster, Pooja Shah, Mark Latymer, Arnold G. Vulto
Biosimilars have improved access to biologic medicines; however, historical thinking may jeopardize the viability of future markets.An expert panel of eight diverse European stakeholders provided i...
-
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-02-01 Abraham Ali, Elizabeth García, Carlos A Torres-Duque, Diana Rey, Laura Botero, Stid Saenz, Maria Paula Avila, Elizabeth Mazo, Sergio Londoño
Cost-effectiveness studies evaluate health technologies and help choose treatments. The current study compared dupilumab to omalizumab, mepolizumab, and benralizumab in Colombian adults with severe...
-
Evaluation instruments for executive functions in children and adolescents: an update of a systematic review Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-31 Arianna Cesari, Giovanni Galeoto, Francescaroberta Panuccio, Rachele Simeon, Anna Berardi
The aim of this study is to update a systematic review of instruments for evaluating the executive functions (EFs) in a pediatric population to assess their measurement properties.Studies describin...
-
Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-30 Elaine Hsuen Lim, Andrew Lim, Jasmeet Singh Khara, John Cheong, Jek Fong, Sivabalan Sivanesan, Matt Griffiths, Emma New, Soo Chin Lee
The Asian PEONY trial showed that add-on pertuzumab to trastuzumab and chemotherapy significantly improved pathological complete response in the neoadjuvant treatment of patients with human epiderm...
-
Economic and humanistic burden in kidney transplant rejection: a literature review Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-29 Emily Moss, Anita Burrell, James Lee, Dawn Reichenbach, Sarah Mitchell, Songkai Yan, Kris Thiruvillakkat
Antibody-mediated rejection (ABMR) is a major cause of late kidney allograft failure, but its economic and humanistic impacts have not been well-characterized in the literature.We reviewed availabl...
-
Drug pricing and transparency in Europe and the United States: what is it and how does it work? Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-26 Steven Simoens, Mondher Toumi
As drug prices are viewed to be opaque, there have been increasing societal demands on policy and decision makers to implement initiatives that promote drug price transparency.This Perspective disc...
-
How should we measure the use of social care and informal care? Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-26 Joanna Thorn, Kirsty Garfield
Published in Expert Review of Pharmacoeconomics & Outcomes Research (Vol. 24, No. 3, 2024)
-
Feasibility assessment of using the MiToS staging system for conducting economic evaluation in amyotrophic lateral sclerosis Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Paulos Gebrehiwet, Saurabh Aggarwal, Ozlem Topaloglu, Adriano Chiò
This study assessed the feasibility of using the Milano-Torino staging (MiToS) system for conducting economic evaluation to measure health outcomes in amyotrophic lateral sclerosis (ALS).A Markov m...
-
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Jorge Mestre-Ferrandiz, Marcin Czech, Josef S. Smolen, Paul Cornes, Matti S. Aapro, Silvio Danese, Stephen Deitch, Hannah Tyldsley, Will Foster, Pooja Shah, Mark Latymer, Arnold G. Vulto
Approved biosimilars exhibit comparable efficacy, safety, and immunogenicity to reference products. This report provides perspectives on the societal value of biosimilars within Europe and potentia...
-
Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Boon Piang Cher, Sharon Goh, Mohamed Ismail Abdul Aziz, Grace Wong, Raymond Ng Chee Hui, Benjamin Shao-Kiat Ong, Kwong-Hoe Ng
To assess the cost-effectiveness of sacituzumab govitecan for treating relapsed or refractory metastatic triple-negative breast cancer (TNBC) in Singapore.A three-state partitioned survival model w...
-
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Manuel Macía, Montserrat Díaz-Encarnación, Roser Solans-Laqué, Elisenda Pomares Mallol, Alejandra García Castells, Cristina Escribano, Antonio Ramírez de Arellano
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) are rare autoimmune diseases characterized by inflammation of blood vessels. This study aimed to assess the cost-utility of avacopan ...
-
Systematic review of the impact of health care expenditure on health outcome measures: implications for cost-effectiveness thresholds Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Mac Ardy Junio Gloria, Montarat Thavorncharoensap, Usa Chaikledkaew, Sitaporn Youngkong, Ammarin Thakkinstian, Nathorn Chaiyakunapruk, Jessica Ochalek, Anthony J. Culyer
Empirical estimates of the impact of healthcare expenditure on health outcome measures may inform the cost-effectiveness threshold (CET) for guiding funding decisions. This study aims to systematic...
-
The role of insurance policies in the drug pricing landscape Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Alexandra Savova, Manoela Manova, Konstantin Tachkov, Guenka Petrova
This overview paper aims at summarizing and analyzing the available literature on healthcare system organization and pricing policies of 11 European countries, comparing them to the Bulgarian pharm...
-
Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Zoltán Kaló, Maciej Niewada, Tamás Bereczky, Wim Goettsch, Rick A Vreman, Entela Xoxi, Mark Trusheim, Marcelien H E Callenbach, László Nagy, Steven Simoens
The uptake of complex technologies and platforms has resulted in several challenges in the pricing and reimbursement of innovative pharmaceuticals. To address these challenges, plenty of concepts h...
-
Social care data in the UK; current landscape, challenges, and future recommendations Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Diana Mendes, Robert Wood, Monica Seif, Shuk-Li Collings
Social care in the United Kingdom (UK) refers to care provided due to age, illness, disability, or other circumstances. Social care provision offers an intermediary step between hospital discharge ...
-
Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Michael J. DiStefano, Antal Zemplenyi, Kelly E. Anderson, Nicholas D. Mendola, Kavita V. Nair, Robert Brett McQueen
The United States has begun assessing the value of pharmaceuticals to inform negotiated prices in the Medicare program. Given strong political objections in the United States to the use of QALYs, M...
-
Developing the Lebanese health economic evaluation guideline Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Caroline Daccache, Rita Karam, Silvia M.A.A. Evers, Mickaël Hiligsmann, Rana Rizk
To report on the process of developing the Lebanese Economic Evaluation Guideline (LEEG), and to provide relevant material that could assist guideline developers in the future.The development of th...
-
Coping with increasing medicine costs through greater adoption of generic prescribing and dispensing in Pakistan as an exemplar country Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Saad Abdullah, Zikria Saleem, Brian Godman
Published in Expert Review of Pharmacoeconomics & Outcomes Research (Vol. 24, No. 2, 2024)
-
Payer and Developer perspectives on alternative payment models Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Renita Moradian, Tsega Meshesha, Mark Trusheim, Jane F Barlow
To understand the use of alternative payment models to address the reimbursement challenges of cell and gene therapies (CGT) in the U.S.A..A literature search focused on CGT reimbursement in the U....
-
Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Shuo Kang, Xiaohui Wang, Zhenhua Pan, Huanlong Liu
The aim of the current analysis was to evaluate the cost-effectiveness of toripalimab plus chemotherapy compared with chemotherapy alone as the first-line option for patients with advanced esophage...
-
Canadian English translation and linguistic validation of the 13-MD to measure global health-related quality of life Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Thomas G. Poder, Moustapha Touré
The 13-MD is a new instrument designed to measure more globally the various aspects of the health-related quality of life. Its structure is balanced around physical, mental, and social aspects of h...
-
Cost-utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Negin Bashari, Majid Safaei Lari, Ali Darvishi, Rajabali Daroudi
Immunotherapy drugs like Pembrolizumab have shown significant improvements in treatment outcomes of advanced melanoma. This study aimed to evaluate the cost-utility of Pembrolizumab compared to oth...
-
Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved? Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-25 Sharon Wolters, Lisa A de Jong, Christel Jansen, Frank GA Jansman, Maarten J Postma
Evidentiary requirements for relative effectiveness assessment vary among European health technology assessment (HTA) bodies, affecting the time to HTA decision-making and potentially delaying time...
-
Fiscal analysis of the pediatric immunization program in Belgium applying a lifetime government perspective framework Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-23 Nikos Kotsopoulos, André Bento-Abreu, Goran Bencina, Mark P. Connolly
A public economic framework was used to explore lifetime government costs and benefits in relation to the Pediatric Immunization Program (PIP) in Belgium based on cases and deaths averted.To estima...
-
Willingness to pay for cancer prevention versus treatment in China: implications for cost-effectiveness threshold Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 Zixuan Zhao, Yi Yang, Weijia Wu, Hengjin Dong
Empirical support for the appropriate cost-effectiveness threshold (CET) in China remains sparse.This study aimed to estimate the willingness to pay (WTP) for cancer prevention and treatment from t...
-
Interview with Julie Frappier, health economist, and creator of the TOWWERS™ System Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 Julie Frappier
Published in Expert Review of Pharmacoeconomics & Outcomes Research (Vol. 24, No. 1, 2024)
-
Systematic reviews of machine learning in healthcare: a literature review Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 Katarzyna Kolasa, Bisrat Admassu, Malwina Hołownia-Voloskova, Katarzyna J Kędzior, Jean-Etienne Poirrier, Stefano Perni
The increasing availability of data and computing power has made machine learning (ML) a viable approach to faster, more efficient healthcare delivery.A systematic literature review (SLR) of publis...
-
Revival? Prospects for a return to comprehensive and coordinated health technology assessment in America Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 Daniel A. Ollendorf
Published in Expert Review of Pharmacoeconomics & Outcomes Research (Vol. 24, No. 1, 2024)
-
Seeing the whole elephant: integrated advanced data analytics in support of RWE for the development and use of innovative pharmaceuticals Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 Won Chan Lee
The 21st century has brought about significant technological advancement, allowing the collection of new types of data from the real world on an unprecedented scale. The healthcare industry will be...
-
Natural language processing – relevance to patient outcomes and real-world evidence Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 Robert Stewart, Jaya Chaturvedi, Angus Roberts
Published in Expert Review of Pharmacoeconomics & Outcomes Research (Vol. 24, No. 1, 2024)
-
Netflix and pill: is there a role for volume-delinked subscription-style payments beyond antimicrobials?’ Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 Grace Hampson, Lotte Steuten
Published in Expert Review of Pharmacoeconomics & Outcomes Research (Vol. 24, No. 1, 2024)
-
Impact of poor medication adherence on clinical outcomes and health resource utilization in patients with hypertension and/or dyslipidemia: systematic review Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 André Pascal Kengne, Jean-Baptiste Brière, Lucía Zhu, Jingya Li, Mandeep Kaur Bhatia, Petar Atanasov, Zeba M Khan
We aimed to summarize evidence on the effect of poor medication adherence on clinical outcomes and health resource utilization (HRU) among patients with hypertension and/or dyslipidemia.A systemati...
-
Economic benefits of global Collaborative Health technology Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 Ahmad Z. Al Meslamani
Published in Expert Review of Pharmacoeconomics & Outcomes Research (Vol. 24, No. 1, 2024)
-
System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 Hadi A. Khorshidi, Deborah Marshall, Ilias Goranitis, Brock Schroeder, Maarten IJzerman
Precision Medicine (PM), especially in oncology, involve diagnostic and complex treatment pathways that are based on genomic features. To conduct evaluation and decision analysis for PM, advanced m...
-
Story completion (SC) – an epistemological approach to the interpretation of patient-reported outcomes? Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 Keith A Meadows, Matt Reaney
Patient-reported outcome measures (PROMs) quantitative data are increasingly accompanied by qualitative narrative data, which does not always provide the insights required to inform healthcare.This...
-
The impact of under-investment on health in Southern and Central Eastern European Countries Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 John Yfantopoulos
Better health improves human capital and is a driver to economic growth. The allocation of resources to national health systems should be prioritized as investment and not expense/cost.The purpose ...
-
Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 Mochong Liao, Shuo Kang
The current study aimed to evaluate the cost-effectiveness of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer (NSCL...
-
Overview and quality assessment of health economic evaluations for homeopathic therapy: an updated systematic review Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-18 Thomas Ostermann, Julia Burkart, Sabine De Jaegere, Christa Raak, Steven Simoens
Likewise other medical interventions, economic evaluations of homeopathy contribute to the evidence base of therapeutic concepts and are needed for socioeconomic decision-making. A 2013 review was ...
-
Adapting Health Technology Assessment agency standards for surrogate outcomes in early stage cancer trials: what needs to happen? Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-09 Kristian Thorlund, Cal Shephard, Lisa Machado, Tara Bourgouin, Lorraine Hudson, Eon Ting, William Dempster, Robert Bick
An avalanche of early stage cancer clinical trials is coming. The majority of these solely use surrogate outcomes that have not been validated against a target outcome of interest (e.g. overall sur...
-
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2024-01-09 Petra Došenović Bonča, Dalibor Gavrić, Karmen Janša, Jože Sambt
The burden of diabetes on individuals, healthcare systems, and society must be explored to improve and sustain diabetes care. With this aim, we estimated both past and future diabetes-related direc...
-
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2023-12-20 Katrina S. Firlik, Vamshi Ruthwik Anupindi, Vincent Hayes, Mitchell DeKoven, Asif Shaikh, Jessica Franchino-Elder
To assess the impact of the HealthPrize RespiPoints™ program on treatment adherence and persistence in adults with chronic obstructive pulmonary disease (COPD).In this retrospective cohort study, p...
-
What to expect in 2024: important health economics and outcomes research (HEOR) trends Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2023-12-21 Ivo Abraham, Mickael Hiligsmann, Kenneth K. C. Lee, Leslie Citrome, Giorgio L. Colombo, Mike Gregg
Published in Expert Review of Pharmacoeconomics & Outcomes Research (Ahead of Print, 2023)
-
Evaluation of Antimicrobial Stewardship Programs and antibiotic prescribing patterns among physicians in ambulatory care settings in Jordan Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2023-12-14 Mera A. Ababneh, Hana Abujuma, Shoroq Altawalbeh, Saddam Al Demour
Currently, there is an urgent need to implement an Antimicrobial Stewardship Program (ASP) in outpatient settings since nearly half of the antibiotic prescribing is inappropriate or unnecessary. Th...
-
Impact of single-pill combinations versus free-equivalent combinations on adherence and persistence in patients with hypertension and dyslipidemia: a systematic literature review and meta-analysis Expert Rev. Pharmacoecon. Outcomes Res. (IF 2.3) Pub Date : 2023-12-13 André Pascal Kengne, Jean-Baptiste Brière, Pauline Le Nouveau, Petya Kodjamanova, Petar Atanasov, Maryse Kochoedo, Omar Irfan, Zeba M. Khan
Hypertension is a leading cause of death and disease burden followed by dyslipidemia. Their asymptomatic nature leads to low adherence and persistence to treatments. A systematic literature review ...